HIF1A and neoplasm: Based on these findings, the prospects of using anti-HIF-1α therapy is not likely to favor TNBC over other tumor groups, however, targeting HIF-1α may still prove beneficial given its definite expression in a significant portion of all studied breast cancer subtypes.